Current Report · Items 8.01 · 8-K

Outlook Therapeutics, Inc.

OTLKNASDAQEQUITYCurrent

Other Events

Item 8.01 Other Events. On September 16, 2026, Outlook Therapeutics, Inc. established the wholesale acquisition cost for LYTENAVA™ in the United States of $485 per vial.

Filed Sep 18, 2026Accepted Sep 18, 2026, 4:30 PM EDTCIK 1649989Accession 0001104659-26-108952

View company →Permanent SEC source ↗

Company context

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg (U.S.), bevacizumab gamma (E.U.)). LYTENAVA is the only ophthalmic formulation of bevacizumab to receive U.S. FDA approval and European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.

Current securities

OTLKNASDAQ · EQUITY · Current

Historical securities (3)

ONSIWNASDAQ · WARRANT · Historical · closed Dec 3, 2024 ONSIZNASDAQ · WARRANT · Historical · closed Dec 3, 2024 OTLKWNASDAQ · WARRANT · Historical · closed Dec 3, 2024

Recent company filings

Registered securities in this filing

Outlook Therapeutics, Inc. · 8-K · Filed 2026-09-18

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock

Symbol: OTLK
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: AsOf2026-09-16

Dimensions: Not supplied

Accession 000110465926108952 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 8.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events

Item 8.01 Other Events. On September 16, 2026, Outlook Therapeutics, Inc. established the wholesale acquisition cost for LYTENAVA™ in the United States of $485 per vial.